Clinical trials: Male Pattern Baldness
Androgenetic Alopecia, Hair Loss
Treatment of Androgenetic Alopecia in Females, 12 Beam
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 12 beam model for androgenetic alopecia in females when treatment is applied as directed.
- Conditions
- Androgenetic Alopecia, Hair Loss, Female Pattern Baldness
- Trial name
- NCT01016964
- Testing
- HairMax LaserComb 2009 model 12 beam
- Where
- 3 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
This study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of N1087 compared with placebo in adult men with androgenetic alopecia (male pattern hair loss).
- Trial name
- MINORA-MEN (NCT07529977)
- Testing
- Minoxidil oral solution
- Volunteers
- 372 people
- Sponsor
- Eurofarma Laboratorios S.A.
Androgenetic Alopecia
Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
The purpose of this study is to evaluate the safety and efficacy of three doses of topical NEOSH101 applied once-daily (qd) for 16 weeks in men with thinning hair in the top and center of the scalp (Norwood/Hamilton grades III-IV…
- Trial name
- NCT00471510
- Testing
- tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Neosil, Inc.
Androgenetic Alopecia (AGA)
A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia
This study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
- Trial name
- NCT07327359
- Testing
- OLX72021
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Olix Pharmaceuticals, Inc.
Androgenetic Alopecia
Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia
Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals.
- Trial name
- NCT01885676
- Testing
- PRGF-Endoret, Saline Solution
- Where
- 2 sites in Spain
- Sponsor
- Biotechnology Institute IMASD
Androgenetic Alopecia
24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness
The purpose of this study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia
- Trial name
- NCT01686295
- Testing
- iRestore Hair Rejuvenation System
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Freedom Laser Therapy, Inc.
Androgenetic Alopecia
Clinical Trial in Females for Female Pattern Hair Loss
This is a six month clinical trial to evaluate the effectiveness and safety in women with Female Pattern Hair Loss (FPHL), comparing a 5% minoxidil topical foam (MTF) formulation applied once a day versus a topical foam vehicle…
- Trial name
- NCT01226459
- Testing
- 5% Minoxidil Topical Foam, Vehicle Topical Foam
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 404 people
- Sponsor
- Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
AGA
A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects
1. To evaluate the safety and tolerability of CU-40101 liniment as a single and multiple topical application in adult male androgenic alopecia subjects； 2.
- Trial name
- NCT05380427
- Testing
- CU-40101
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
Androgenetic Alopecia
Treatment of Androgenetic Alopecia in Males and Females
The purpose of this study is to evaluate the efficacy of Low Level Laser and Light Therapy system configured in a novel product called the TopHat 655 system, for promoting hair growth in males and females diagnosed with…
- Trial name
- LLLT (NCT01437163)
- Testing
- TopHat 655 rejuvenation system, Laser and/or Light Hair Rejuvenation System
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Apira Science, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)
Evaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451190
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 9 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia
The purpose of this study is to evaluate the safety and efficacy in relation to dosing in the administration of Hair Stimulating Complex (HSC) in healthy men.
- Trial name
- HSC Phase I/II (NCT01501617)
- Testing
- Hair Stimulating Complex (HSC), Dulbecco's Modified Eagle Medium, DMEM
- Where
- Philippines
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Histogen
Alopecia
Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Treatment of male pattern hair loss (MPHL) or androgenetic alopecia (AGA) with 5α-reductase inhibitor (5-ARIs) has been associated with sexual dysfunction including erectile dysfunction and loss of libido.
- Trial name
- NCT02014584
- Testing
- Dutasteride
- Where
- 18 sites in Chile, Hong Kong and 3 more
- Volunteers
- 117 people
- Sponsor
- Stiefel, a GSK Company
Androgenetic Alopecia
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
The study is designed to validate efficacy and long term safety of PP405.
- Trial name
- AWAKEN (NCT07819435)
- Testing
- PP405 0.05% Topical Gel, Vehicle Topical Gel
- Where
- 63 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Pelage Pharmaceuticals, Inc.
Androgenetic Alopecia
Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO
This is a prospective, randomized double-blind, multi-center study to evaluate the efficacy of low level laser therapy over-the-counter at home device Theradome LH80 PRO, compared to SHAM for promoting hair growth in males…
- Trial name
- NCT02528552
- Testing
- LH80 PRO
- Where
- 4 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Theradome, Inc.
Androgenetic Alopecia, Hair Loss
Treatment of Androgenetic Alopecia in Males
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 7 Beam model in promoting hair growth in males diagnosed with androgenetic alopecia when treatment is applied as directed.
- Conditions
- Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
- Trial name
- NCT00947505
- Testing
- HairMax LaserComb 2009, 7 Beam, HairMax LaserComb
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Androgenetic Alopecia
Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration
The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following…
- Trial name
- NCT04984707
- Testing
- KX0826
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.
- Trial name
- NCT02279823
- Testing
- CB-03-01 solution, Minoxidil Solution 5%
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- Intrepid Therapeutics, Inc.